Genetic Diseases and Pharmacogenomics

August 2011 | 75 pages | ID: G7A3C64F220EN
Venture Planning Group

Abstracts

Global PDF: US$ 1,900.00

This report presents:

• Overview of the clinical significance and market needs for major genetic diseases
• Reviews the field of pharmacogenomics
• Provides listings of companies developing and marketing NAT technologies and products.

Contains 75 pages

Contents

1. OVERVIEW

2. NUCLEIC ACID AMPLIFICATION

3. CHROMOSOME IMAGING

4. GENOMICS TECHNOLOGIES

5. PROTEOMICS TECHNOLOGIES

6. CURRENT PHARMACOGENOMIC TESTS

7. FUTURE PHARMACOGENOMIC TESTING

8. MAJOR DISEASES

• Achondroplasia
• Autosomal Dominant Polycystic Kidney Disease
• Cancer
• Cosmetogenomics
• Cystic Fibrosis
• Down's Syndrome
• Duchenne and Becker Muscular Dystrophy
• Factor V (Leiden)
• Factor IX Deficiency
• Fragile X Syndrome
• Heart Disease
• Hemochomatosis
• Hemophilia
• Huntington's Disease
• Maternal-Fetal Incompatibility
• Multiple Endocrine Neoplasia
• Phenylketonuria (PKU)
• Polycystic Kidney Disease (PKD)
• Prenatal Screening
• Retinitis Pigmentosa
• Retinoblastoma
• Sickle Cell Anemia
• Spinal Muscular Atrophy
• Vitamin B12 Metabolism

9. SOCIAL ISSUES AND CONCERNS

Table: Major Companies Developing or Marketing
Molecular Diagnostic Tests For Genetic Diseases